Literature DB >> 25278701

NANOG: a promising target for digestive malignant tumors.

Ai-Xi Sun1, Chang-Jiang Liu1, Zi-Qin Sun1, Zhi Wei1.   

Abstract

NANOG has been extensively researched since its discovery by Chambers et al. NANOG is a homeodomain transcription factor and an essential regulator of embryonic stem cell (ESC) self-renewal, which inhibits differentiation. Cancer stem cells (CSCs) are a small subset of cells that are thought to drive uncontrolled tumor growth; CSCs retain the tumor capabilities of self-renewal and propagation. The existence of CSCs was recently shown by direct experimental evidence. NANOG is expressed in CSCs and ESCs, although it remains unclear whether ESCs and CSCs share similar mechanisms in the regulation of physical and biological processes. Several studies suggest that the expression level of NANOG is high in cancer tissues and low or absent in normal tissues. High levels of NANOG expression are associated with advanced stages of cancer and a poor prognosis, indicating that it plays a vital role in tumor transformation, tumorigenesis, and tumor metastasis. NANOG is part of a complex regulatory network that controls cell fate determination, proliferation, and apoptosis. NANOG cooperates with other regulators, such as microflora, transcription factors, and kinases, in cancer cells. NANOG might have a promising future in anti-cancer and other therapeutic treatments, which could improve human health.

Entities:  

Keywords:  Anti-cancer; Cancer stem cells; Gastrointestinal tumor; NANOG

Mesh:

Substances:

Year:  2014        PMID: 25278701      PMCID: PMC4177486          DOI: 10.3748/wjg.v20.i36.13071

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  90 in total

1.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

2.  Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells.

Authors:  Jai-Hee Moon; Suhyun Kwon; Eun Kyoung Jun; Aeree Kim; Kwang Youn Whang; Hyunggee Kim; Sejong Oh; Byung Sun Yoon; Seungkwon You
Journal:  Biochem Biophys Res Commun       Date:  2011-07-23       Impact factor: 3.575

3.  Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.

Authors:  Juanjuan Shan; Junjie Shen; Limei Liu; Feng Xia; Chuan Xu; Guangjie Duan; Yanmin Xu; Qinghua Ma; Zhi Yang; Qianzhen Zhang; Leina Ma; Jia Liu; Senlin Xu; Xiaochu Yan; Ping Bie; Youhong Cui; Xiu-wu Bian; Cheng Qian
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

4.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.

Authors:  Hyenjong Hong; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Osami Kanagawa; Masato Nakagawa; Keisuke Okita; Shinya Yamanaka
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

5.  Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.

Authors:  Shih-Hwa Chiou; Mong-Lien Wang; Yu-Ting Chou; Chi-Jen Chen; Chun-Fu Hong; Wang-Ju Hsieh; Hsin-Tzu Chang; Ying-Shan Chen; Tzu-Wei Lin; Han-Sui Hsu; Cheng-Wen Wu
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

6.  Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma.

Authors:  Ting Lin; Yan-Qing Ding; Jian-Ming Li
Journal:  Med Oncol       Date:  2011-02-20       Impact factor: 3.064

7.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

Review 9.  FAK and p53 protein interactions.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Anticancer Agents Med Chem       Date:  2011-09       Impact factor: 2.505

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  4 in total

1.  Endothelial cells activate the cancer stem cell-associated NANOGP8 pathway in colorectal cancer cells in a paracrine fashion.

Authors:  Rui Wang; Rajat Bhattacharya; Xiangcang Ye; Fan Fan; Delphine R Boulbes; Ling Xia; Lee M Ellis
Journal:  Mol Oncol       Date:  2017-06-06       Impact factor: 6.603

2.  Oncogenic NanogP8 expression regulates cell proliferation and migration through the Akt/mTOR signaling pathway in human gastric cancer - SGC-7901cell line.

Authors:  Zheng Jiang; Yao Liu; Chuan Wang
Journal:  Onco Targets Ther       Date:  2016-08-09       Impact factor: 4.147

Review 3.  NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?

Authors:  Sten Friberg; Andreas M Nyström
Journal:  J Nanobiotechnology       Date:  2016-03-09       Impact factor: 10.435

4.  Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells.

Authors:  Alessandro Corsaro; Adriana Bajetto; Stefano Thellung; Giulia Begani; Valentina Villa; Mario Nizzari; Alessandra Pattarozzi; Agnese Solari; Monica Gatti; Aldo Pagano; Roberto Würth; Antonio Daga; Federica Barbieri; Tullio Florio
Journal:  Oncotarget       Date:  2016-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.